Naturewise Biotech & Medicals Corporation

As of June 30, 2026, Naturewise Biotech & Medicals Corporation carries a market capitalization of 831.03M, placing it among publicly traded companies globally. Its enterprise value stands at 451.07M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Naturewise Biotech & Medicals Corporation has 48.46M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Naturewise Biotech & Medicals Corporation maintains a current ratio of 7.05, meaning it holds 7.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Naturewise Biotech & Medicals Corporation's stock has declined approximately 25.12% over the past 52 weeks. The 50-day moving average sits at 17.35, while the 200-day moving average is 18.62.

As of June 30, 2026, Naturewise Biotech & Medicals Corporation holds 409.13M in cash and equivalents against 31.63M in total debt, resulting in a net debt position of -104.51M. Total book value stands at 557.32M, with working capital of 495.58M providing operational flexibility.

Naturewise Biotech & Medicals Corporation's most recent stock split took place on September 13, 2021 with a 50:53 split ratio.